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Review
COVID-19: Coagulopathy, Risk
of Thrombosis, and the Rationale for
Anticoagulation
Wolfgang Miesbach, MD1 and Michael Makris, MD2,3
Abstract
The novel coronavirus infection (COVID-19) is caused by the new coronavirus SARS-CoV-2 and is characterized by an exag-
gerated inflammatory response that can lead to severe manifestations such as adult respiratory syndrome, sepsis, coagulopathy,
and death in a proportion of patients. Among other factors and direct viral effects, the increase in the vasoconstrictor angiotensin
II, the decrease in the vasodilator angiotensin, and the sepsis-induced release of cytokines can trigger a coagulopathy in
COVID-19. A coagulopathy has been reported in up to 50% of patients with severe COVID-19 manifestations. An increase in D-
dimer is the most significant change in coagulation parameters in severe COVID-19 patients, and progressively increasing values
can be used as a prognostic parameter indicating a worse outcome. Limited data suggest a high incidence of deep vein thrombosis
and pulmonary embolism in up to 40% of patients, despite the use of a standard dose of low-molecular-weight heparin (LMWH) in
most cases. In addition, pulmonary microvascular thrombosis has been reported and may play a role in progressive lung failure.
Prophylactic LMWH has been recommended by the International Society on Thrombosis and Haemostasis (ISTH) and the
American Society of Hematology (ASH), but the best effective dosage is uncertain. Adapted to the individual risk of thrombosis
and the D-dimer value, higher doses can be considered, especially since bleeding events in COVID-19 are rare. Besides the
anticoagulant effect of LMWH, nonanticoagulant properties such as the reduction in interleukin 6 release have been shown to
improve the complex picture of coagulopathy in patients with COVID-19.
Keywords
COVID-19, thrombosis, anticoagulation
Date received: 12 May 2020; revised: 17 May 2020; accepted: 8 June 2020.
Introduction
Coronaviruses (CoVs) consist of a large family of single-
stranded RNA viruses, identified decades ago but whose
clinical significance and epidemic potential were not recog-
nized until the outbreak of severe acute respiratory syndrome
CoV (SARS-CoV) and Middle Eastern respiratory syndrome
(MERS) in 2002 and 2012, respectively. They can cause
symptoms ranging from a mild cold to severe respiratory
diseases, with mortality rates of 10% for SARS and 37%
for MERS.1,2
Severe acute respiratory syndrome CoV 2, the causative
agent of COVID-19, is the seventh member of the CoV to be
identified and is structurally similar to SARS-CoV, with the 2
viruses sharing about 72% of their genome.3 Severe acute
respiratory syndrome CoV 2 poses a major threat to global
health that goes far beyond the spread and risks of SARS-
CoV and MERS. In addition to significant mortality, another
key issue of COVID-19 is the exponential increase in the
number of infected patients and the very high number of
patients in hospitals.
Severe acute respiratory syndrome CoV 2 and other CoVs
show similarities and differences. Both viruses can cause fatal
lung diseases and appear to be particularly dangerous for
elderly people or people with comorbidities.
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Like other CoVs, SARS-CoV-2 uses the angiotensin-2
receptor (ACE2) to enter the target cells, but with a higher
affinity for ACE2.3 After binding to its receptor, ACE2 acti-
vates the renin–angiotensin system (RAS), which leads to a
downregulation of ACE2 expression, resulting in an increase
in angiotensin II (Ang II) and a decrease in its counterpart
angiotensin.1-7 In contrast to SARS-CoV infection, however,
SARS-CoV-2 infection seems less likely to be fatal. The mor-
tality rate varies from country to country and depends on the
capacity and performance factors of the health care systems.
Despite significantly higher mortality rates for SARS and
MERS, COVID-19 has led to more deaths overall due to the
high number of infected individuals. By April 16, 2020, more
than 2.1 million persons had been infected and more than 142
000 have died of the disease.5
While most patients show only mild symptoms,6 a charac-
teristic feature of COVID-19 is that a proportion of patients
develop severe complications within a short time after infec-
tion, such as adult respiratory syndrome (ARDS) or dissemi-
nated intravascular coagulation (DIC), sepsis followed by
organ failure, and death.7 Coagulopathy and thrombotic events
have been described in patients with COVID-19, and this
review summarizes existing reports and treatment recommen-
dations in patients with CoV infections.
Coagulopathy and Thrombosis in SARS
and MERS
Severe acute respiratory syndrome CoV first appeared 18 years
ago.8During the SARS-CoV epidemic in 2002, more than 8000
infected patients and 744 deaths were documented in 26 coun-
tries on 5 continents. The main clinical manifestations were
upper respiratory symptoms, rapid progression of pneumonia,
and about 20% to 30% had to be admitted to intensive care
units.9 In patients over 65 years of age, the mortality rate was
over 50%. Of the patients treated or dying in the intensive care
unit, 11.4% developed DIC. In contrast, the mortality rate from
sepsis is much lower with an incidence between 75 and 300 per
100 000.10
In 2012, a new related zoonotic CoV was identified in the
Middle East, the MERS, which causes severe respiratory dis-
ease with a mortality rate of over 35%.11 Despite the high
mortality in both infections, there is no systematic evaluation
of the risk of thrombosis and the incidence of thrombosis.
There is only 1 case report of pulmonary embolism (PE) in
patients with SARS12 and 1 case of ischemic stroke.13 Other
publications reported various clinical and laboratory abnorm-
alities, but no thromboembolic events. A cohort study of 157
SARS patients found no evidence of venous thrombosis or
other clotting abnormalities, such as the presence of antibodies
to cardiolipin or elevated D-dimer concentrations.14 An analy-
sis of laboratory data found that with the exception of throm-
bocytopenia in 55% of patients and a prolonged activated
partial thromboplastin time (aPTT; 40.1-68.1 seconds) in
63%, other coagulation parameters remained unchanged. No
elevated D-dimer levels were found except in the 2.5% of the
160 patients who developed DIC. Another study with 138
SARS patients from 2003, 23.2% of whom were admitted to
intensive care, showed that the peak D-dimer levels were ele-
vated and platelet count was reduced in patients receiving
intensive care or death compared to patients not receiving
intensive care.15 These laboratory changes are consistent with
previous studies which showed that hypoalbuminemia, lym-
phopenia, and C-reactive protein4 mg/dL were the predictive
factors for the progression of pneumonia to respiratory failure
in MERS-CoV-infected patients and that elevated lactate dehy-
drogenase (LDH) levels were associated with hospital-acquired
infection with SARS-CoV.16
Coagulopathy and Thrombotic Risk
in COVID-19
Similar to SARS and MERS, there is a link between inflamma-
tion and severe organ damage in COVID-19 patients. The pri-
mary pathology is ARDS, which is characterized by diffuse
alveolar damage including hyaline membranes. The viral cyto-
pathic effect of pneumocytes implies direct viral damage.17
There is now evidence that some patients may respond to
COVID-19 with an exuberant “cytokine storm” response.18
Immunological studies have demonstrated that pro-
inflammatory cytokines interleukin 6 (IL-6), IL-17A, and
tumor necrosis factor a were elevated in the majority of
patients with severe outcomes.19 Hypercoagulability is an
important hallmark of inflammation. Pro-inflammatory cyto-
kines are critically involved in abnormal clot formation and
platelet hyperactivation and also play an important role in the
downregulation of important physiological anticoagulant
pathways.20
Other patient-related, pneumonia-related, and SARS-
CoV2-related factors can lead to a significantly higher risk
of thrombotic complications in patients with COVID-19
(Table 1). In COVID-19, risk factors for the development of
severe symptoms are advanced age, male sex, and presence of
comorbidities, especially in hypertension where a hazard ratio
(HR) of 1.70 to 3.05 for death has been demonstrated.21,22 In
general, hypertension was identified as an independent risk
factor for deep vein thrombosis in a large prospective study
involving more than 18 000 patients.23 Elderly patients and
Table 1. Factors Increasing the Risk of Thrombosis.
Patient related Pneumonia related SARS-CoV-2 related
Age ICU Angiotensin "
Male sex Central vein catheters Cytokines "
Hypertension Endothelial damage and
increase of FVIII/VWF
Tissue factor "
Cardiovascular
morbidity
Increase of HIF-1 PAI-1"
Immobilization
Abbreviations: HIF-1, hypoxia-inducible factor; ICU, intensive care unit; PAI,
plasminogen activator inhibitor-1; SARS-CoV-2, severe acute respiratory syn-
drome corona virus 2; VWF, von Willebrand factor.
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those with comorbidities are more likely to develop severe
complications of COVID-19 infection and have a higher risk
of thrombosis.24-26
The RAS plays an important role in COVID-19, with
angiotensin-converting enzyme 2 (ACE2) acting as a func-
tional SARS-CoV-2 receptor, resulting in the downregulation
of ACE2 and higher expression of Ang II.27,28 Angiotensin-
converting enzyme 2 is predominantly expressed by the vas-
cular endothelial cells of the lung, but also in extrapulmonary
tissue, heart, nervous system, intestine, kidneys, blood vessels,
and muscles on cell surfaces, which may explain the multi-
organ dysfunction observed in patients with COVID-19.29
Angiotensin II is known to be one of the most potent vasocon-
strictors30 and also increases hypercoagulability by increasing
expression of tissue factor31 and plasminogen activator inhibi-
tor 1. Markedly elevated Ang II levels have been reported in
patients with COVID-19.32
Coagulopathy has been described in studies that document
clinical and laboratory changes in COVID-19 patients in up to
50% of those with severe manifestations.22 Several studies
confirm the relevance of elevated D-dimer concentrations in
COVID-19. Besides the known variability in healthy volun-
teers and their tendency to increase with age, there is an asso-
ciation of elevated D-dimer levels and fibrin degradation
products under all conditions with an activated coagulation
system, such as thrombosis, infection, or malignancy.33
The increase in D-dimer was the most significant change in
coagulation parameters in COVID-19 patients and occurred
more frequently than other coagulation parameters such as pro-
thrombin time (PT) or aPTT.34 Furthermore, the coagulation
parameters indicate a marked tendency to thrombosis, as the
changes of other parameters indicating a bleeding tendency,
such as severely low platelets or fibrinogen levels, were absent.
Comparing the result from severely to nonseverely affected
patients, the median fibrinogen levels, with the exception of
28.6% where the fibrinogen levels were below 1 g/L, increased
to supraphysiological values (5.16 g/L, interquartile range
[IQR]: 3.74-5.69 g/L), and the antithrombin levels remained
in the normal range. Remarkably, increased D-dimers measured
at hospital admission could predict a severe outcome for
COVID-19. In a multivariate analysis comparing clinical and
laboratory parameters of 137 survivors to 54 nonsurvivors, the
mortality odds ratio [OR] for D-dimer levels > 0.5 mg/mL was
2.14, for D-dimer levels > 1 mg/mL was 18.42, while for a PT
>16 seconds,22 the OR was 4.62. The death of the patients
occurred at a median of 18 days of hospital treatment after the
patients were mechanically ventilated for 14.5 days. All 54
deceased patients developed sepsis (100% vs 42% of survi-
vors), 53 patients suffered from respiratory failure (98% vs
36%), 50 patients suffered from acute respiratory failure
(ARDS; 93% vs. 7%), 28 patients suffered from heart failure
(52% vs 12%), and 38 patients suffered from septic shock (70%
vs 0%). The deceased patients were significantly older (64 +
20.7 years vs 52.4+ 15.6 years), significantly more male, and
with chronic diseases (57.1% vs 38.9%). In summary, coagulo-
pathy occurred in 50% of patients who died versus in 7% of
patients who survived. Other serious complications included
acute heart damage (59% vs 1%), acute kidney damage (50%
vs 1%), and secondary infections (50% vs 1%). In patients who
died of COVID-19, the sepsis-related organ failure assessment
(SOFA) score was 4.5 points at admission, while the survivors’
score was only 1.0.
A large study that included 1099 COVID-positive patients
from 552 hospitals in China found that D-dimer concentrations
above the threshold of 0.5 mg/L were observed in 46.4% of the
patients; 60% of them developed severe manifestations. In
these patients, D-dimer levels of 2.12 mg/mL (0.77-5.27) were
4 times higher26 compared to nonseverely affected patients
(0.61 mg/mL, 0.35-1.29). Thus, D-dimer concentration and
SOFA score provide, in addition to the age of the patient,
important information on the prognosis of COVID-19 disease.
Other risk factors for a severe outcome were lymphopenia,
leukocytosis, and increased laboratory values of alanine ami-
notransferase, LDH, highly sensitive troponin I, creatine
kinase, serum ferritin, IL-6, PT, creatinine, and procalcitonin.24
Incidence of Thrombosis in COVID-19
Patients
Laboratory and imaging studies found an increased risk of
thrombotic complications in patients with COVID infection.
The precise incidence of thrombosis in patients with COVID-
19 has not been determined. There are large studies from China
that investigate the clinical course of COVID-19 patients.
However, there was no evidence for the presence of thrombo-
sis, PE, or arterial thrombotic complications: A summary of a
report on 72 314 COVID-19 cases from the Chinese Center for
Disease Control and Prevention mentioned only the age range
of the affected patients with 14.8% in patients aged 80 and
that a critical course occurred in 5% of patients with a mortality
rate of 49%.35 In a study of 1099 COVID-positive patients from
552 hospitals in China, the high frequency of elevated D-dimer
values in 46.4% of patients was highlighted, without, however,
further investigating its influence on the thrombotic risk.26
When patients were specifically screened for the presence of
thrombosis, a remarkably high rate was identified (Table 2).
These studies included patients with varying degrees of disease
severity. In a retrospective evaluation of 138 patients, both the
thrombotic risk (using the Padua prediction score) and the
bleeding risk were assessed. A total of 16.67% of mostly cri-
tically ill patients with a high risk for thrombotic events were
identified, of which 17.3% were diagnosed with deep vein
thrombosis36 despite the use of guideline-recommended throm-
boprophylaxis. Deep vein thrombosis was diagnosed by ultra-
sound 3 to 18 days after hospital admission. The most frequent
Padua risk parameters were acute infections (100%), heart or
respiratory failure (39.9%), limited mobility (15.2%), and age
(12.3%). These criteria continued to increase in critically ill
patients and led to significantly higher score values.36
Patients with COVID-19 pneumonia also have a high risk of
PE, and a rising D-dimer value facilitates the diagnosis of a
thromboembolic event. Out of 1008 hospitalized patients, 25
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with confirmed pneumonia underwent computed tomography
pulmonary angiography.37 Pulmonary embolism was
diagnosed in 40% mainly localized in small branches of the
pulmonary artery. Interestingly, these patients showed signifi-
cantly higher median D-dimer levels (11.07 mg/mL; IQR: 7.12-
21.66) compared to median D-dimer levels of 2.44 mg/mL
(IQR: 1.68-8.34) in patients without PE.
In a single-center retrospective study, 81 patients with
COVID-19 were described who had to be admitted to an inten-
sive care unit and the incidence of deep vein thrombosis was
determined. The patients did not receive thromboprophylaxis.
Twenty patients (25%) had DVT of the lower extremities, 40%
of whom died. The incidence of PE was not systematically
investigated. The use of a D-dimer cutoff >1.5 mg/mL to predict
DVT showed a sensitivity of 85% and a specificity of 88.5%.38
The occurrence of thrombosis has also been reported in
patients using prophylactic low-molecular-weight heparin
(LMWH). A study of 184 patients with COVID-19 pneumonia
from 3 Dutch hospitals investigated the incidence of sympto-
matic acute PE, DVT, ischemic stroke, myocardial infarction,
or systemic arterial embolism in COVID-19 patients admitted
to intensive care.39 There was a 31% incidence of thrombosis.
All patients received at least standard doses for LMWH throm-
boprophylaxis, although schedules differed between hospitals
and doses increased over time. In 9.2%, therapeutic anticoagu-
lation was administered on admission. It is remarkable that
none of the patients developed DIC. The majority of patients
suffered from PE (81%), but a thrombotic stroke occurred in 3
patients.39 Coagulopathy and changes in global coagulation
markers and spontaneous prolongation of PTT and PT
were independent predictors of thrombotic complications
(PT >3 seconds and aPTT >5 seconds; adjusted HR: 4.1;
95% CI: 1.9-9.1).
Arterial thrombosis has also been reported. Of 241 patients,
5.7% suffered from acute cerebrovascular disease,40 1 patient
additionally from of ischemia in the lower limbs bilaterally as
well as in two fingers. In these patients, an unusual combina-
tion of antiphospholipid antibodies with the presence of IgA
anticardiolipin and anti-b2 glycoprotein I IgA and IgG antibo-
dies was detected raising the question of the role of antipho-
spholipid antibodies. However, these were antibodies detected
on a single occasion and no titers were given, so by definition
did not satisfy the criteria for antiphospholipid syndrome.
It was not clear from the clinical studies whether the throm-
botic pulmonary complications were PE or primary pulmonary
thrombosis, as only a small number of deep vein thromboses
were detected in these patients.
The results of autopsy studies indicate the presence of pul-
monary endothelial damage and microthrombosis. In a case
series of 4 autopsies of COVID-19-infected patients from New
Orleans with sudden respiratory decompensation, it was shown
that there were no thromboembolisms in the major pulmonary
arteries, but small thrombi were present in sections of the per-
ipheral lung parenchyma.41 Furthermore, the microscopic find-
ings confirmed that small vessels contained thromboembolisms
and small thrombi together with scattered areas of diffuse
alveolar damage, indicating that small vessels can a be affected
by microthrombosis. D-dimers determined near the time of
death were elevated in only 2 of the 4 patients.
In another case series of 27 autopsies, SARS-CoV-2 was
detected in the endothelial cells of several organs, with the
highest concentrations found in the respiratory tract and lower
concentrations in the kidneys, liver, heart, brain, and blood.42
Therefore, tissues beyond the respiratory tract may be affected,
which may contribute to the clinical course of COVID-19 and
possibly exacerbate preexisting conditions. This suggests that
SARS-CoV-2 may lead to a generalized inflammatory response
of the endothelium, causing fatal organ failure.
A further postmortem analysis found diffuse endothelial
inflammation,43 which may explain why many COVID-19
patients die not only from pneumonia but also from multiple
organ failure due to severe microcirculation disorders, activa-
tion of complement pathways, and a related procoagulant state.
Patients with preexisting endothelial dysfunction (high blood
pressure, cardiovascular disease, or diabetes) are therefore
more likely to be affected.
The Rationale for Individualized Use
of Anticoagulation in COVID-19
The clinical spectrum of infection with the novel SARS-CoV-2
ranges from the absence of any symptoms to fatal septic shock.
The transition from mild to severe in patients with COVID-19
may be caused by cytokine storms and increased hypercoagul-
ability. As with all coagulopathies, treatment of the underlying
disease is mandatory.
For COVID-19, it is advisable to offer prophylactic antic-
oagulation with LMWH as early as possible to prevent throm-
botic events and organ damage. This was recommended in the
recently published preliminary International Society on
Table 2. Incidence of Thrombotic Events.
Study Patients (n) Severity of disease Thrombotic event Use of LMWH
Xu et al36 23 Critically ill and high risk of thrombosis DVT in 17,3% Yes
Chen et al37 25 Proven COVID-19 pneumonia PE in 40% Yes in 80%
Cui et al38 81 Severe and nonsevere DVT in 25% No
Klok et al39 184 Proven COVID-19 pneumonia 31% (81% PE) Yes
Zhang et al40 241 Critically ill Stroke in 5.7% ND
Abbreviations: DVT, deep vein thrombosis; LMWH, low-molecular-weight heparin; ND, not determined; PE, pulmonary embolism.
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Thrombosis and Haemostasis (ISTH) guidance on the detection
and treatment of coagulopathy in COVID-19.44 The ISTH gui-
dance document provides risk stratification on the admission of
COVID-19 patients and treatment of a potentially developing
coagulopathy. It suggests that patients with an elevated D-dimer
(ie, arbitrarily defined as a 3- to 4-fold increase) should be
admitted to hospital. Low-molecular-weight heparin should
be considered in all patients who need to be hospitalized for
COVID-19 infection unless contraindicated.
Bleeding can be caused by DIC and sepsis, which are com-
mon in severe cases. In a study by Tang et al fromWuhan, 71%
of nonsurvivors of COVID-19 infection met the ISTH criteria
for DIC compared to 0.4% of survivors.34 However, a signifi-
cant reduction in other clotting parameters such as platelets or
antithrombin, the most commonly associated with DIC, has not
been described and no bleeding events have been reported even
in severe cases of COVID-19.
In a study of 449 patients with severe COVID-19 manifesta-
tions, 99 of them received heparin (mainly LMWH) for 7 days
or longer.45 The 28-day mortality between heparin users and
nonusers was compared; comparison was also made with
regard to the different risk of coagulopathy stratified by the
sepsis-induced coagulopathy score (SIC) and D-dimer value.
D-dimer, PT, and age were positively and platelet count was
negatively correlated with 28-day mortality in multivariate
analysis. No difference in 28-day mortality was found between
heparin users and nonusers (30.3% vs 29.7%, P ¼ .910). How-
ever, the 28-day mortality of heparin users was lower than that
of nonusers in patients with SIC score 4 (40.0% vs 64.2%,
P ¼ .029) or D-dimer >6 times the upper limit of normal value
(32.8% vs 52.4%, P ¼ .017).
Several nonanticoagulant properties of LMWH have also
been suggested, such as the reduction of the release and biolo-
gical activity of IL-6.46,47 Low-molecular-weight heparin has
been shown to bind to SARS-CoV-1 and block replication of
the virus.48 Recently, the anti-inflammatory effect of LMWH
was confirmed in patients with COVID-19 with lower IL-6
levels and higher lymphocyte levels compared to COVID-19
patients not treated with LMWH, while changes in other
inflammatory factors were not statistically significant.49 In
addition, initially elevated levels of D-dimer and fibrinogen
degradation products decreased significantly after treatment
with LMWH, indicating an improvement in hypercoagulable
state in COVID-19 patients. The clinical benefit of LMWH
may be due to its effect on inhibiting the release of IL-6
together with the increase in lymphocytes that can delay or
block the inflammatory cytokine storm.
Although the concept of using LMWH in any hospitalized
COVID-19 patient is generally accepted, there is a debate about
the dosage to be employed. Since there are reports that throm-
bosis occurred despite low-dose prophylactic use of LMWH,
dose escalation of LMWH can be employed either empirically
or based on increasing D-dimer values. Ideally, we should wait
for the randomized clinical trials to report first, but the impact
of the disease now means that decisions may be made empiri-
cally and are largely based on opinion.
However, the most reliable approach to evaluating the
effects of new drugs is randomized clinical trials. Even in the
event of epidemics or pandemics and the urgent need for rapid
and effective treatment, randomized trials should be conducted
as early as possible. In uncontrolled trials, several multiple
drugs could be selected without testing a clear risk–benefit
ratio in the typically variable clinical courses of new diseases.50
Antithrombotic Treatment in COVID-19
Patients
Therapeutic anticoagulation is the cornerstone for the treatment
of thrombosis and PE. For the treatment of venous thromboem-
bolism in intensive care units, unfractionated heparin is typi-
cally preferred because of its short mode of action and no
known interaction with any of the investigational drugs of
COVID-19.51 However, frequent monitoring is required, and
monitoring with aPTT may be compromised by increased
activity of the acute phase protein FVIII. In this case, the aXa
test should be preferred.
Longer acting agents, such as LMWH, may also be consid-
ered. It can be administered subcutaneously once or twice daily
and does not require frequent monitoring to ensure that it is
effectively dosed.
Oral anticoagulants, including warfarin, the direct thrombin
inhibitor dabigatran, and the factor Xa inhibitors apixaban,
rivaroxaban, edoxaban, and betrixaban, should not be consid-
ered for the treatment of thrombosis in COVID-19 patients,
inter alia, because of possible interactions with antiviral
therapeutics.51
In 3 severe cases of COVID-19-related ARDS, intravenous
administration of recombinant tissue plasminogen activator
was used. The authors reported a temporary improvement in
respiratory failure even in the absence of manifest PE, suggest-
ing the contribution of lung microthrombi in the prothrombotic
state of COVID-19.52
Finally, autopsy findings of endothelial cell infections,
endotheliitis, and microthrombosis may lead to an additional,
more targeted treatment with endothelial stabilizing drugs,
such as anti-inflammatory drugs, anticytokines, ACE inhibi-
tors, and statins.
Summary
There is a growing understanding of the pattern of COVID-19
not only in epidemiology and immunology but also in subse-
quent coagulopathy and coagulopathy treatment strategies.
COVID-19 is associated with a hypercoagulable state, and
infected patients with additional risk factors have a worse out-
come. Initial data suggest high thromboembolism rates in
patients without and often with standard pharmacological
thromboprophylaxis. Limited data also suggest that localized
pulmonary microvascular thrombosis may play a role in the
progressive respiratory failure. Most evidence is limited by
small retrospective studies, and the true prevalence of throm-
bosis in COVID-19 still needs to be evaluated in larger studies.
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Severe complications of COVID-19 occur more frequently
in older patients with comorbidities, and this group of individ-
uals also have an age-related increased risk of thrombosis. The
high risk of thrombosis in COVID-19 is demonstrated by the
increase in D-dimer, which was found to be the most significant
change in coagulation parameters in COVID-19 patients, sug-
gesting increased thrombin production and activation of
fibrinolysis.
Despite the fact that D-dimer is a nonspecific acute phase
reactant and may be elevated by other causes and inflamma-
tion, it has been shown that a consecutive increase in D-dimer
may indicate the presence of thrombosis and PE in critically ill
COVID-19 patients. A significant reduction in other, coagula-
tion parameters such as platelets, fibrinogen, or antithrombin,
which are most frequently associated with DIC, has not been
frequently described, neither have bleeding events during
COVID-19. There is therefore a need to identify the increased
risk of thrombotic events at an early stage and to prevent
thrombotic events and organ damage as far as possible. Pro-
phylactic anticoagulation with LMWH should be initiated as
soon as possible to prevent thrombotic events and counteract
the pro-inflammatory influence of cytokines and other factors.
The incidence of thrombosis in critically ill patients is high
and thrombotic events occurred despite the prophylactic use of
LMWH. There is an urgent need for the results from rando-
mized trials regarding the appropriate antithrombotic prophy-
laxis and treatment. Risk stratification according to D-dimer
values may be an option to individualize treatment or to use
higher doses even taking into account the complex thrombotic
picture of COVID-19.
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